PharmaThene receives payment from Biomedical Advance Research and Development Authority
The contract expired Feb. 28.
Future government funding to support the development of SparVax is unlikely, PharmaThene officials said.
"Even if we received such funding, significant additional non-clinical animal studies, human clinical trials and manufacturing development work remain to be completed for all of our product candidates," a statement from PharmaThene said. "It is also uncertain whether any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans."
Copies of PharmAthene's public disclosure filings are available at www.PharmAthene.com.